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Sllnlt't'lsry 
The class II transactivator (CIITA) has been shown to be required for major histocompatibility 
complex (MHC) class II gene expression in B cells and its deficiency is responsible for a hereditary 
MHC class II deficiency. Here we show that CIITA is also involved in the inducible expression 
of class II genes upon interferon "y (IFN-~) treatment. The expression of CIITA is also inducible 
with IFN-3' before the induction of MHC class II mRNA. In addition, CIITA mRNA expression 
does not require new protein synthesis,  although new protein synthesis is necessary for the 
transcription of class II. This suggests that synthesis of new CIITA protein may be essential 
to induce class II gene expression. We also showed that the JAK1 protein tyrosine kinase activity 
is required to induce the expression of CIITA upon IFN-3' stimulation. This finding indicates 
that CIITA is part of the signaling cascade from the IFN-3, receptor to the activation of class 
II genes. In addition, the expression of CIITA is sufficient to activate class II genes in the absence 
of IFN-3,  stimulation suggesting that CIITA is the major regulatory factor for the inducible 
expression  of class II genes.  Together, these data suggest that CIITA is  the IFN-inducible 
cycloheximide sensitive factor previously shown to be required for the induction of MHC class 
II gene expression. 
M 
ajor histocompatibility complex (MHC)-encoded class 
II antigens are heterodimeric cell surface molecules that 
present antigens to CD4 positive lymphocytes and thus play 
a important role in the regulation of immune responses. The 
expression of MHC class II molecules is developmentally 
regulated, and only limited cell types normally express class 
II antigen, primarily antigen-presenting cells such as macro- 
phages, dendritic cells, and B cells. Class II expression can 
be induced on human T cdls by mitogens or antigens (1-3) 
and on macrophages, fibroblasts,  and endothelial cells by 
IFN-'y (4). 
The molecular mechanisms responsible for the regulation 
of MHC class II gene expression in B cells has been exten- 
sively studied (reviewed in 5). Many c/s regulatory elements 
have been identified and DNA-binding proteins that could 
potentially be involved in the regulation of class II gene ex- 
pression have been characterized.  However, relatively  little 
is known about the molecular mechanisms of IFN-3' induc- 
tion of class II genes. The IFN-',/induction of cell surface 
MHC class II antigens is mediated by an increase in steady 
state mRNA. Previous  work showed that this increase in 
steady state mRNA is due, at least in part, to an increased 
rate of transcription (6-8). In HeLa cells, macrophages, and 
a human osteosarcoma cell line this induction can be blocked 
by cycloheximide, implying that de novo synthesis of an in- 
termediate factor(s)  is required (6-8). 
IFNs regulate gene expression by tyrosine phosphoryla- 
tion of several transcriptional factors that share the 91-kD 
protein (termed Stat91  for signal transducer and activator 
of transcription) of IFN-stimulated gene factor 3 (ISFG3) as 
a common component (9-15). ISGF3 binds to a specific  DNA 
sequences,  IFN-stimulated response dement (ISRE),  and 
directs IFN-dependent gene transcription. Stat91 is also known 
as the IFN-~/-activated factor (GAF)  that binds the IFN-qr 
activation sequence (GAS)  1 in the promoter of the guanylate- 
binding protein (GBP)  gene (9,  15). Although analysis of 
the nuclear response of class II genes to IFN-3~ has defined 
the DNA sequences required for the IFN response to a min- 
imal promoter region from - 136 to + 10 bp of HLA-DRA 
and this promoter sequence is suificient for both IFN-3~ in- 
duction and basal expression on a transient assay (16, 17), 
neither ISRE nor GAS sequences have been found in this re- 
1  Abbreviations used in this paper: CIITA, class II transactivator; GAS, INF-'y 
activation sequence. 
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isolated which is responsible for the IFN-inducible expres- 
sion of class  II genes. 
Although the expression of MHC class II genes in fibro- 
blasts can usually be induced with IFN-3, treatment, we found 
that fibrosarcoma LTK-  cells are not able to express either 
IE or IA class II molecules. In addition it has been shown 
that LTK- ceils are unable to mount to an antiviral response 
and to transcribe IFN-3-inducible genes to IFN-B treatment 
(18-20). However, the expression of MHC class I and invar- 
iant chain genes are inducible upon IFN-3, treatment (Chang, 
C.-H., unpublished data). We, therefore, undertook a genetic 
approach to find the regulatory factor(s) that can activate class 
II  genes  in  LTK-  calls.  Here we report  that  the  class  II 
transactivator  (CIITA) is able to activate the expression of 
class II genes in LTK-  ceils and suggest a model in which 
CIITA is the key IFN-inducible  factor required for MHC 
class  II gent expression. 
Materials  and Methods 
Cell Culture.  An cell lines are  maintained  in  DMEM  sup- 
plemented with 10% FCS and 2 mM glutamine.  Murine IFN-'y 
(GIBCO BILL, Gaithersburg,  MD) was used at  100 U/m1 and 
human  IFN-3, (gift from Biogen, Cambridge,  MA) was used at 
concentration  of 500 U/ml. 
Transfection.  For genomic transfection, 80 #g of genomic DNA 
with 1 #g of linearized hygromycin DNA were coprecipitated into 
LTK- cells using calcium phosphate.  2 d after transfection, cells 
were split  1:2 into  medium containing  400 #g of bygromycin 
(Calbiochem-Novabiochem Corp., San Diego, CA). The same pro- 
cedure was employed for the transient transfection except that 25 
#g of DNA was used and cells were harvested 2 d after transfection. 
Construction ofCIITA cDNA.  The CIITA cDNA, which has 
SalI sites at each end in the cloning linkers, was subcloned into 
the SalI site ofpUC19. An oligonucleotide, coding for the 8 amino 
acid flu-tag on the 5' end,  as well as the first 19 amino acids of 
CIITA was subdoned into the EcoRI site ofpUC19 and the unique 
DraIII  site of CIITA.  The flu-CIITA (from EcoKI to SalI) was 
then  moved from pUC19 into  pCDNA/amp  (Invitrogen,  San 
Diego, CA) into the EcoRI and XhoI sites. 
Flow Cytometry Analysis.  Cells  were  stained for IE  surface 
expression with 14.4.4S (PharMingen,  San Diego,  CA), for IA 
expression with  10-3.6.2 (21) and secondary staining  was per- 
formed with FITC-conjugated goat anti-mouse IgG (Southern Bio- 
technology Associates, Birmingham,  AL). The stained ceils were 
analyzed using FACStar  |  (Becton Dickinson  & Co.,  Mountain 
View, CA). 
PCR.  RNA was prepared as described (22). First strand cDNA 
was synthesized by reverse transcriptase (Seikaguku America, Inc., 
Rockville, MD) using  10 ng of oligo dT as a primer  and 2 #g 
of cytoplasmic KNA in 10 mM Tris-HC1 (pH 8.3), 50 mM KC1, 
1.5 mM MgClz,  0.01%  gelatin,  1 mM dithiothreitol,  and 200 
mM deoxynucleotides. PCR amplification was performed using 
1/10 of synthesized first strand cDNA, 5 U of Taq DNA poly- 
merase (Perkin-Elmer Cetus, Norwalk, CT) in the reaction condi- 
tion same as for first strand synthesis. 30 cycles were run at 1 min 
at 94~  1 min at  55~  and 3 rain  at 72~  After the PCR 
amplification reaction,  one half of PCR products  were analyzed 
by ethidium bromide staining in agarose gels using standard tech- 
niques (23). The sequences of oligonucleotides  for primers used 
in PCK amplification are as follows: Eol sense, CCAGAAGTC- 
ATGGC~TATCA in exon 1; Fax antisense, GC~TCCTTGTCG- 
GCGTTCTA in exon 4;  DRc~ sense, CGAGTTCTATCTGAA- 
TCCTG  in  exon 2;  DKc~ antisense,  GTTCTC~TGCATTC~- 
TTTTGC in exon 4; CIITA sense, CAAGTCCCTGAAGGATGT- 
GGA; CIITA antisense, ACGTCCATCACCCGGAGGGAC; actin 
sense, CACCCTGTGCTGCTCACCGAGGCC;  actin antisense, 
CCACACAGATGACTTGC GCTCAGG. 
Results 
Genomic Transfiction.  There are several lines of evidence 
suggesting that the positive regulatory factor(s) required for 
MHC class II gene expression is not present in LTK- cells. 
First, we found that both the IE and IA MHC class II genes 
are not induced in LTK-  cells  upon murine  IFN-3' treat- 
ment although a normal response of class I expression is ob- 
served  (Chang,  C.-H.,  unpublished  data).  Second,  when 
LTK-  cells were fused with MHC class II positive human 
B cells, the endogenous mouse class II gent was reexpressed 
(Chang,  C.-H.,  unpublished  data).  We,  therefore,  chose 
LTK-  celIs to study the regulatory factors that mediate the 
expression of class  II genes. 
To done a gene capable of complementing  the defect in 
LTK- cells, genomic DNA prepared from human cells was 
cotransfected with the hygromycin marker gent. Hygromycin 
resistant colonies were pooled from each plate of cells,  in- 
duced with mouse IFN-% and tested for class II expression 
by PCK. One pool (no. 9) was identified by PCR as positive 
for Ecx mRNA and class II positive cells were sorted using 
flow cytometry after staining with the antibody to IE. Eight 
clones were isolated after a limiting  dilution  of the sorted 
population of IE positive ceils. They showed a similar pat- 
tern of class II expression on cell surface (data not shown). 
One clone, 9.18A4, which shows inducible expression of both 
IE and IA upon IFN-'y treatment (Fig. 1 A) was further charac- 
terized and used for the subsequent experiments.  To deter- 
mine whether the gene of interest was linked to the hygro- 
mycin marker gent, secondary transfection was performed. 
Genomic DNA prepared from 9.18A4 was transfected back 
into  LTK-  cells without  the  addition  of the  hygromycin 
plasmid. Out of 19 hygromycin resistant colonies, 6 class II 
positive clones were isolated, suggesting that the gent of in- 
terest was physically linked to the marker gent. A third round 
of transfection was carried out using the genomic DNA from 
either class II positive or negative secondary transfectants. 
Tertiary transfectam, class II positive clones were isolated from 
hygromycin resistant clones but only from the DNA prepared 
from class II positive transfectants, not from negative trans- 
fectants (Fig.  1, B  and  C). 
The Expression of CIITA in Ciass lI Positive Transfectants.  Re- 
cently, a new regulatory factor,  CIITA,  for the expression 
of MHC class II genes was isolated and characterized (24). 
To determine  whether  this  factor was responsible for the 
phenotype observed in LTK-  transfectants,  CIITA expres- 
sion was tested. Since the message of CIITA is reported to 
be low (24), reverse transcriptase-PCR analysis was employed 
instead of Northern  analysis.  As shown in Fig.  2, all class 
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II positive transfectants show signals for both class II and 
CIITA, whereas all class II negative cells show neither. As 
a positive control, Raji human B lymphoma cells, were used 
to show normal class II and CIITA. Because  we observed 
the same PCR product for CIITA using both mouse and 
human (data  not  shown),  it  was  necessary  to  determine 
whether the PCR products from the transfectants were of 
human or mouse origin. To identify the origin of CIITA the 
PCR products from transfectants were isohted and sequenced. 
Sequence  analysis showed that the PCR product from the 
transfectants have the identical sequence to human CIITA 
not mouse suggesting that CIITA expressed in transfectants 
is derived from the transfected human gene (data not shown). 
Although the levels of class II and CIITA are increased after 
the induction with IFN-v, both genes were expressed at low 
level even before the IFN-3, treatment (compare hnes of unin- 
duced and induced with IFN-'y) as is commonly observed 
in inducible cell lines. 
The Expression of CIITA Is Su.~cient to Activate the Expres- 
sion of Class II Genes.  Although we showed that there is 
a very good correlation between the presence of CIITA and 
the  IFN-inducible  expression  of class II  genes  in  LTK- 
transfectants, it still does not prove the requirement of  CIITA 
for MHC class II gene expression.  We therefore transfected 
the eDNA for CIITA into LTK- calls to test whether class 
II genes can be activated. As shown in Pig.  3, Eol mILNA 
is present in LTK- ceils transfected with CIITA eDNA but 
not with control DNA.  In addition ceils transfected with 
CIITA express IE on cell surface (data not shown). It should 
be noted that E(x mRNA is present at the same level with 
or without the IFN-v treatment (Fig. 3, lane 3 and 4) sug- 
gesting that the overexpression  of CIITA which is directed 
by a constitutive, non-IFN-inducible promoter seems to be 
sufficient to activate class II genes without IFN-v induction. 
IFN~" Induction of CIITA.  The  data from  the LTK- 
transfectants suggested a model in which the endogenous 
CIITA expression is induced by IFN-v treatment and that 
this is responsible for MHC class II induction (see Fig. 2). 
Therefore, the expression of CIITA was tested at different 
time points after the addition of  IFN-3, to the medium. CIITA 
expression is detectable without IFN-v but the level is gradu- 
Figure  1.  Cell  surface  expression of class II molecules,  IE and IA, on 
transfectants. (A) Primary  transfectants  (9.18A4) and parent LTK- cells 
were stained. Cells were stained  with either IE or IA antibodies. Cells 
were stained  with secondary  antibody  alone (  ), class II antibodies 
followed  by the secondary  antibody  before the IFN-3, induction  (- - -), 
and class II antibodies  after  IFNw induction  (-.-). Results  are expressed 
as relative  cell number (y-axis)  vs. log fluorescence  intensity  (x-axis). (/3) 
Tertiary  transfectants  with DNA from  class  II positive  secondary  transf~c- 
rants. Solid line represents the chss II staining  without IFN-3' induction 
and broken  line  represents  after  IFNw induction.  (C) Tertiary  transfectants 
with DNA from class II negative secondary transfectants. 
Figure  2.  Expression  of  CIITA  and class  II gene  in transfect~mts.  PCK 
analysis  was performed  using primers for both CIITA and class II genes. 
Bottom shows  actin as a control. Lanes  marked  with + are cells treated 
with murine  IFN-  V (100 U/ml) for 2 d. The data are representative  of 
three independent analyses. 
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CIITA cDNA. LTK- cells were transfeeted transiently  with either con- 
trol DNA or CIITA cDNA. Cells were harvested 2 d after the transfec- 
tion and RNA was analyzed by reverse  transcriptase-PCR.  -/+ represents 
the absence/presence of mouse IFN-% 9.18 is the clone which is class II 
positive LTK- transfectant with human genomic DNA as described in 
the text. 
ally enhanced as the incubation time increases suggesting that 
the expression of CIITA is under the IFN~ control (Fig. 
4).  The maximum level of CIITA mRNA is observed be- 
tween 12 and 18 h, which is significantly earlier than dass 
II mRNA induction  which reaches a maximum at 24 h (com- 
pare the intensity of two bands in Fig. 5, lane I  and 2). The 
fact that CIITA is expressed before MHC class II is consis- 
tent with its requirement for dass II expression, since CIITA 
mRNA should be first translated into protein to induce class 
II mRNA. 
The Effect  of  Cydoheximide on the Ex~n  of  CIITA.  We, 
and others showed previously that the transcription of class 
II genes requires de novo protein synthesis (6-8).  To deter- 
mine whether the expression of CIITA also require protein 
synthesis,  ceils were treated with either IFN-3', cyclohexi- 
mide to block protein synthesis,  or both IFN-3,  and cyclo- 
heximide and tested for the expression of class II and CIITA 
at different time points. As shown in Fig. 5 (lanes I-3), both 
class II and CIITA expression are inducible upon IFN-7 treat- 
ment. Class II is not expressed with cycloheximide alone al- 
Figure 4.  Effect  of IFN-3r on CIITA and class II (DRa) gene tran- 
scription. Hda cells  were incubated with medium containing human IFN~ 
(500 U/ml), and cells were harvested and RNA was prepared at given 
time points.  Reverse transeriptase-PCIL  analysis was performed  using 
primers for both CIITA and DRa genes. The data are representative of 
three independent analyses. 
though the level of CIITA is slightly increased by the same 
treatment (Fig. 5, lanes 4-6). The level of dass II expression, 
however, is dramaticafiy reduced upon treatment with IFN-7 
and cydoheximide  (Fig. 5, lanes 7-9). Since the level of CIITA 
mRNA is not affected by cycloheximide, unlike MHC class 
II, the induction of CIITA gene expression does not require 
new protein synthesis. 
CIITA Expression  Requires  Kinase Activity.  Akhough the 
expression of CIITA does not require new protein synthesis, 
the regulation of CIITA must be mediated by IFN-7 sig- 
naling (Figs.  2 and 4).  We have described recently mutant 
ceils that are unresponsive to IFNs (25). These mutant ceils 
exhibit a complete loss of all IFN-7 responses as well as the 
IFN-a induction of class I and other IFN-indudble genes. 
It has been shown that these mutants have a defect in the 
protein tyrosine kinase JAKI (26) as has also been found for 
the similar  mutant U4 isolated by Muller et al.  (27).  We, 
therefore,  tested the expression of CIITA in these cells. As 
shown in Fig. 6 (lanes 1 and 2) the mutant cell ling E1C3, 
does not express CIITA or class II genes upon IFN-3' treat- 
ment. To determine whether a functional  JAK1 can comple- 
ment the defect, mutant cells were transfected with the  JAK1 
gene. mRNAs for class II as well as CIITA was induced in 
Figure 5.  Effect  of cycloheximide of CIITA and class 
II gene transcription.  HeLa cells were exposed to human 
IFN-7 (500 U/m1) or cycloheximide (5/~g/ml) alone, or 
to a combination  of IFN-v/CHX for 12, 18, and 24 h. 
Reverse transcriptase-PCR analysis is described in the 
legend to Figure 3. The data are representative of three 
independent  analyses. 
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E1C3, were  transfected  with DNA shown  at the top. RNA was analyzed 
by PCR. -/+ represents  the absence/presence  of  human  IFN-3,. The data 
are representative  of three independent  analyses. 
JAKl-transfected ceils after IFN-3, treatment but not in cells 
transfected with JAK2, a related protein tyrosine kinase (Fig. 
6, lanes 3-4). The data suggest that protein tyrosine kinase 
activity is required to induce CIITA expression. 
We also tested whether the expression of CIITA can by- 
pass the IFN-3, signaling defect in these mutants. Interest- 
ingly, the mutant calls transfected  with CIITA cDNA ex- 
press class II genes even before IFN-3' induction, suggesting 
that the overexpression of CIITA is sufficient to activate class 
II genes without IFN-3~ induction (Figs.  3 and 6). 
Discussion 
Although the mechanism of class II expression has been 
studied extensively  over the years, it is still  not dear how 
dass II genes are regulated by IFN; many DNA binding pro- 
teins have been isolated and characterized, but their functional 
significance is in many cases unclear. The reverse genetic ap- 
proach that we have taken has led us the demonstration that 
CIITA, first identified as a gene responsible for the BLS (24) 
affecting class II expression on human B cells, is a regulatory 
factor for IFN-3' inducible expression of class II genes. The 
study demonstrates first that, the regulatory factor, CIITA, 
can participate in the activation of the IFN-q,-mediated ex- 
pression of class II genes and that it is itself also inducible 
with IFN-3/(Figs.  1-4).  Second,  the expression of CIITA 
is sufficient for the inducible expression of class II genes (Figs. 
3 and 6). Third, the induction of CIITA requires protein tyro- 
sine kinase activity (Fig. 6). Although our transfected LTK- 
cells are  derived from a done (9.18A4),  after  subsequent 
growth there is a bimodal distribution of class II positive 
population (Fig.  1, A  and B). This may due to the segrega- 
tion and loss of the CIITA gene during passaging of cells 
which  suggests  that  the  CIITA  gene  is  integrated  at  a 
significant  distance from the hygromycin gene. This is sup- 
ported by the fact that genomic cloning, and "walking" ex- 
periments covering more than 60 kb of the DNA flanking 
the hygromycin gene has not revealed the CIITA gene. 
1371  Chang  et al. 
Both IE and IA expression  are induced by CIITA in the 
complemented  LTK- cells implying that CIITA is involved 
in the regulation of both genes. Since the expression of the 
MHC  class  I  and invariant genes are  induced by IFN  in 
LTK- cells without functional CIITA protein, CIITA is pre- 
sumably not involved in the regulation of these genes by IFN-'y 
stimulation. In addition, BLS-2 cells have normal levels of 
class I and invariant  chain supporting the idea that CIITA 
is not the regulatory factor that directs the expression of these 
genes in B cells (Chang, C.-H., unpublished data).  It is not 
clear at this point whether CIITA is responsible  for the ex- 
pression of other IFN-3,-inducible genes. 
CIITA is upregulated upon IFN stimulation before class 
II induction. The comparison of the kinetics of CIITA and 
dass II indicates that the increase of the transcription of CIITA 
precedes MHC class II transcription which is consistent with 
the hypothesis that CIITA may be required for the expres- 
sion of class II genes. It should be noted that CIITA is ex- 
pressed at a low level, even before IFN-3, treatment, but MHC 
class II expression is undetectable which suggests that this 
low basal level of CIITA may not be sufficient  to activate 
class II expression to detectable levels, or that CIITA, or other 
proteins needs to be activated  by IFN-3'.  We consider the 
latter possibility ~nlikdy, however, since transfection of CIITA 
into our mutant cell line that cannot respond to IFN-3' is 
sufficient for MHC class II gene expression.  Alternatively, 
the uninduced level of CIITA transcripts detected by PCR 
may not be physiologically significant.  It is interesting that 
the class II positive LTK-  transfectants show basal levels of 
both CIITA and class II mRNA which increase substantially 
upon IFN-'r treatment although they do not exhibit cell sur- 
face expression ofdass II protein before IFN induction (com- 
pare Figs. 1 and 2). Basal expression of transfected, inducible 
genes is commonly  seen and may be due to the fact that CIITA 
gene has  integrated into  a chromosomal environment in 
LTK-  cells such that the transfected CIITA shows a low 
basal level of transcription. It is, therefore, possible that the 
level of CIITA transcripts could be the limiting factor for 
the induction of the class II gene transcription. In addition, 
the level of class II mRNA detected by PCR may be still 
below the threshold required for detectable cell surface ex- 
pression by flow cytometry. 
It has been shown that the transcription of class II requires 
new protein synthesis  (6-8).  Data from our cydoheximide 
study suggests that the CIITA translation may be necessary 
for class II expression  because cydoheximide treatment in- 
hibits the synthesis of CIITA protein without affecting its 
transcription. Consequently, we suggest that in the absence 
of CIITA protein the class II genes can not be inhibited. In- 
terestingly, the level of CIITA transcripts was slightly en- 
hanced with cydoheximide. The mechanism of the induc- 
tion by cydoheximide treatment is not dear. 
It has been suggested by Steimle et al.  (24)  that CIITA 
does not bind to DNA directly and that instead it may act 
as a coactivator through protein-protein interactions. The 
promoter of DR-o~ in BLS-2 cells, which lack CIITA, shows 
the same binding pattern seen in normal cells (28,  29)  al- 
though BLS-2 cells do not express class II genes because of Figure 7.  Schematic  model of IFN-~/pathway for the activation of class 
II gene. Ligand binding to the receptor triggers  the phosphorylation  of 
JAK1 and JAK2 kinase, which then activates CIITA by either directly 
or through an intermediate  such as Stat91. 
the defect in CIITA (24). Gel shift mobility assays  using dass 
II negative cells also demonstrated that there is no significant 
difference in the pattern of DNA binding proteins (Chang, 
C.-H., unpublished data).  In addition, in vivo footprinting 
studies showed that no IFN-~/-specific DNA binding site was 
induced after IFN-y induction (30)  suggesting that IFN- 
",/-mediated transcription is not the result of the induction 
of a unique IFN-3,-responsive  DNA binding protein that ac- 
tivates transcription. These interesting results indicate that 
DNA binding proteins already occupy the class II promoter 
in BLS-2 without CIITA or possibly LTK-  cells but that 
this promoter is not transcriptionally active. 
It is interesting that JAK1 tyrosine kinase activity is neces- 
sary for the induction of CIITA. Tyrosine phosphorylation 
has emerged as a major component of the signal transduc- 
tion mechanism for both IFN-ot (11, 31-33) and IFN-3, (11, 
14, 15, 31, 33-36). TYK2 is involved in the signaling pathway 
for the type I IFNs (33) and JAK2 is required for the IFN-3, 
pathway (36,  see Fig.  7); JAK1 is involved in the signaling 
of both interferons (26,  27).  Although our data using the 
mutant cells, E1C3, show that JAK1 is required for the in- 
duction of class II gene expression by interferon, the inter- 
mediate molecules between the IFN-3' receptor and the class 
II gene had not been identified. The data presented here show 
a clear cause and effect relationship between the presence of 
CIITA and the expression of dass II. The mutant cells that 
are defective in JAK1 protein tyrosine kinase activity do not 
show any induction of class II or CIITA mRNA but the trans- 
fection of functional JAK1 into these cells restores  the ex- 
pression of both. Moreover, the transfection of CIITA eDNA 
into mutant cells also induces the expression of dass II gene 
suggesting that CIITA is the key transcriptional factor for 
IFN-'),-indudble expression of class II genes. We do not know 
the mechanism whereby JAK1 mediates its effects nor how 
many steps are involved.  It seems that the induction of en- 
dogenous CIITA requires a phosphoprotein  (see  below) which 
has to be phosphorylated by a tyrosine kinase. 
The induction of most genes by IFN-3, is mediated by the 
phosphorylation of the transcription factor Stat91 (9, 15, 37). 
Stat91 is a phosphoprotein and is one of the components of 
the well-characterized  ISGF3  transcription factor complex 
(10-14).  Although the components of the ISGF3 complex 
are phosphorylated by IFN-a/B, Stat91 is the only protein 
of this complex that can be phosphorylated by both IFN- 
ot/fl and -3/(9-11,  13, 15, 32). The expression of MHC class 
II is only inducible upon IFN-'y not by -cffB. There is, how- 
ever, no evidence for a direct involvement of Stat91 in class 
II gene expression.  In addition, CIITA mRNA is not in- 
duced by IFN-o~ (data not shown). It is, nonetheless, reason- 
able to postulate that the promoter of CIITA may contain 
GAS, the sequence that can be recognized by Stat91  upon 
IFN-y induction and that the binding of Stat91 activates the 
CIITA gene resulting in the induction of the class II genes 
(Fig. 7). This hypothesis is further supported by our obser- 
vation  that  JAK1-  mutant  HeLa  cells  transfected  with 
CIITA cDNA driven by the CMV viral promoter express 
class II genes in the absence of IFN-3,  induction. 
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